RxDoctor Payments Data

Vijaykumar Karumbunathan, MD

Internal Medicine · Crisfield, MDNPI 1174589386

Payments from drug & device makers

$2,379in general payments, 2019–2025

Across 131 payments — averaging $18.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$308
  • Pfizer$279
  • UCB, Inc.$231
  • AstraZeneca$190
  • Otsuka America Pharmaceutical, Inc.$175
  • Scpharmaceuticals Inc.$149
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$2,36499%
  • Education$151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,379 in reported general payments places this provider in the 80th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$219,090
Medicare patients
573
Services billed
2,744

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban854$409,448
JardianceEmpagliflozin495$291,160
EntrestoSacubitril/Valsartan263$160,512
FarxigaDapagliflozin Propanediol373$158,045
OzempicSemaglutide148$152,704
RexultiBrexpiprazole206$146,900
MounjaroTirzepatide68$78,665
RybelsusSemaglutide55$64,720
Trelegy ElliptaFluticasone/Umeclidin/Vilanter91$60,983
KerendiaFinerenone112$54,161
XareltoRivaroxaban65$48,744
LinzessLinaclotide82$46,061
ProliaDenosumab24$44,734
XifaxanRifaximin12$37,643
MyrbetriqMirabegron123$34,124

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Nurtec Odt$279$442,605877 claims
Boehringer IngelheimJardiance, Synjardy, Tradjenta$122$318,660534 claims
Novo NordiskOzempic, Rybelsus$121$217,424203 claims
AstraZenecaFarxiga, Brilinta$190$168,992420 claims
NovartisEntresto$97$160,512263 claims
Otsuka America Pharmaceutical, Inc.Rexulti$175$146,900206 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Arexvy, Shingrix$121$127,933292 claims
Lilly USA, LLCMounjaro, Trulicity$22$103,53792 claims
AbbVieLinzess, Qulipta, Restasis$308$83,073134 claims
MerckJanumet, Januvia, Verquvo$69$73,60095 claims
BayerKerendia$17$54,161112 claims
AmgenProlia$73$44,73424 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Crisfield

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →